AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26626272 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort analysis
Number of subjects: 382
Study 26627079 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg)
Number of subjects: 15
Study 26627079 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (350 mg)
Number of subjects: 15
Study 26627079 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (200-350 mg)
Number of subjects: 15
Study 26627079 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib
Number of subjects: 15
Study 26627107 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, TAF 10 mg)
Number of subjects: 242
Study 26627107 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 242
Study 26628448 — intervention group
Group type: EXPERIMENTAL
Intervention: STAMP scoring system
Number of subjects: 60
Study 26628448 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified STAMP
Number of subjects: 60
Study 26628448 — intervention group
Group type: EXPERIMENTAL
Intervention: STAMP
Number of subjects: 60
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC/FENO ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1/FENO ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FEF25-75%/FENO ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO/FVC ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO/FEV1 ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO/FEF25-75% ratio
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FEF25-75%/FENO and FENO/FEF25-75% values
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC/FENO, FEV1/FENO, and FEF25-75%/FENO
Number of subjects: 1529
Study 26628565 — intervention group
Group type: EXPERIMENTAL
Intervention: New lung function/lung inflammation ratios
Number of subjects: 1529
Study 26628614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 0.9 mg/kg
Number of subjects: 4
Study 26628614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 3.0 mg/kg
Number of subjects: 4
Study 26628614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 9.0 mg/kg
Number of subjects: 4
Study 26628614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 13.5 mg/kg
Number of subjects: 4
Study 26628614 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT)
Number of subjects: 4
Study 26628838 — intervention group
Group type: EXPERIMENTAL
Intervention: EVL plus somatostatin (250 mcg/hr)
Number of subjects: 61
Study 26628838 — intervention group
Group type: COMPARATOR
Intervention: EVL plus placebo
Number of subjects: 61
Study 26629367 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 86
Study 26630396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors, 88% at entry, 87% after 1 year)
Number of subjects: 151
Study 26630396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors)
Number of subjects: 151
Study 26630918 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1
Number of subjects: 0
Study 26630918 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1 derivatives
Number of subjects: 0
Study 26631084 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ECG monitoring using an implantable loop recorder for 12 months.
Number of subjects: 0
Study 26631084 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group) matched by age and sex.
Number of subjects: 0
Study 26631428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20, 40, 80, 120, and 160 mg/d
Number of subjects: 0
Study 26631428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone doses <120 mg/d
Number of subjects: 0
Study 26631428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (multiple doses)
Number of subjects: 0
Study 26631428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (adverse events)
Number of subjects: 0
Study 26631691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ) used for 2 weeks
Number of subjects: 118
Study 26631691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ) used for 1 month
Number of subjects: 118
Study 26631691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ)
Number of subjects: 118
Study 26631736 — intervention group
Group type: COMPARATOR
Intervention: Ob-MSCs (mesenchymal stem cells from infants born to obese mothers)
Number of subjects: 29
Study 26631736 — intervention group
Group type: COMPARATOR
Intervention: Ob-MSCs
Number of subjects: 29
Study 26631736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride inhibition of GSK-3β
Number of subjects: 29
Study 26631736 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipogenic differentiating cells
Number of subjects: 29
Study 26632544 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0
Study 26632544 — intervention group
Group type: COMPARATOR
Intervention: brivanib
Number of subjects: 0
Study 26632544 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin-based or gemcitabine-based regimen
Number of subjects: 0
Study 26632544 — intervention group
Group type: EXPERIMENTAL
Intervention: capecitabine
Number of subjects: 0
Study 26632544 — intervention group
Group type: COMPARATOR
Intervention: other treatments
Number of subjects: 0
Study 26632544 — intervention group
Group type: EXPERIMENTAL
Intervention: antiviral treatment
Number of subjects: 0
Study 26632544 — intervention group
Group type: EXPERIMENTAL
Intervention: nutritional treatment
Number of subjects: 0
Study 26632545 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy strategies including vaccines, adaptive therapy, immune checkpoint blockades, and cytokines.
Number of subjects: 0
Study 26632639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 106
Study 26632639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with impaired QoL
Number of subjects: 106
Study 26632639 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study 26632823 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivery
Number of subjects: 197
Study 26632823 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivery with local salaries and core laboratory tests
Number of subjects: 197
Study 26632823 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivery with lower salaries and lowest ART prices
Number of subjects: 197
Study 26632823 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally efficient scale-up model
Number of subjects: 197
Study 26632823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost breakdown
Number of subjects: 197
Study 26632880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced pain (CHIP)
Number of subjects: 15
Study 26632880 — intervention group
Group type: EXPERIMENTAL
Intervention: Present pain experiences
Number of subjects: 15
Study 26632880 — intervention group
Group type: EXPERIMENTAL
Intervention: Future pain expectations
Number of subjects: 15
Study 26633472 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing animal protein with plant protein (median level of ~35% of total protein per day)
Number of subjects: 280
Study 26633622 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Number of subjects: 55
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at the 15q25 locus (containing CHRNA3/5, AGPHD1, IREB2, CHRNB4)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic region on chromosome 4 (upstream of HHIP)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 1 (TGFB2)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 9 (DBH)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 19 (CYP2A6/7)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 4 (FAM13A)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 11 (MMP3/12)
Number of subjects: 9919
Study 26634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 14 (RIN3)
Number of subjects: 9919
Study 26635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood complete molecular remission monitoring every 3 months
Number of subjects: 94
Study 26635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular relapse confirmed on subsequent peripheral blood sample
Number of subjects: 94
Study 26635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow complete molecular remission
Number of subjects: 94
Study 26635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of minimal residual disease
Number of subjects: 94
Study 26635076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 299
Study 26635076 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced eGFR (continuous variable)
Number of subjects: 299
Study 26635076 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of cardiac mechanics (after adjustment)
Number of subjects: 299
Study 26635230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers (CYP3A5*1 allele carriers)
Number of subjects: 164
Study 26635230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 nonexpressers (homozygous CYP3A5*3)
Number of subjects: 164
Study 26635230 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CYP3A5 expressers and nonexpressers)
Number of subjects: 164
Study 26635230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers
Number of subjects: 164
Study 26635230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 nonexpressers
Number of subjects: 164
Study 26635965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention followed by standard fertility treatments after 6 months if no conception has been achieved
Number of subjects: 100
Study 26635965 — intervention group
Group type: COMPARATOR
Intervention: Standard fertility treatments only
Number of subjects: 100
Study 26635965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100
Study 26636013 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend prescribing (Friday to Sunday)
Number of subjects: 30
Study 26636013 — intervention group
Group type: COMPARATOR
Intervention: Weekday prescribing (Monday to Thursday)
Number of subjects: 30
Study 26636489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch
Number of subjects: 0
Study 26636489 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 26637464 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapies (ACTs) during early pregnancy
Number of subjects: 0
Study 26637464 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without malaria
Number of subjects: 0
Study 26637464 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women treated for malaria but exposed to other antimalarials
Number of subjects: 0
Study 26637464 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women with malaria treated with artemisinins in the 2nd or 3rd trimesters
Number of subjects: 0
Study 26637645 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST) of the less-affected ankle dorsiflexor muscles, 16 to 18 high-intensity training sessions
Number of subjects: 8
Study 26637645 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST)
Number of subjects: 8
Study 26638054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET) using treadmill (n=96) and cycle-ergometer (n=106)
Number of subjects: 202
Study 26638054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET) using treadmill (n=96)
Number of subjects: 202
Study 26638054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test (CPET)
Number of subjects: 202
Study 26639081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 54
Study 26639348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (150 to 1200 mg per day in dose-escalation phase; up to 400 mg per day in expansion cohort)
Number of subjects: 116
Study 26639348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg per day)
Number of subjects: 116
Study 26639348 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 116
Study 26639390 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 15
Study 26639404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible caspase-9 gene (iC9) safety switch expressed by donor-derived T lymphocytes, activated by chemical inducer of dimerization (CID).
Number of subjects: 4
Study 26639404 — intervention group
Group type: EXPERIMENTAL
Intervention: iC9-T cells detectable post-CID.
Number of subjects: 4
Study 26639404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector insertion sites (VIS) in iC9-T cells pre- and post-CID administration.
Number of subjects: 4
Study 26639404 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of VIS locations.
Number of subjects: 4
Study 26639404 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal iC9 transgene expression.
Number of subjects: 4
Study 26640039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg daily) combined with Rituximab (375 mg/m2 IV once per week for 4 weeks, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years)
Number of subjects: 50
Study 26640039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with Rituximab
Number of subjects: 50
Study 26640780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized trivalent bispecific antibody (TF2) and IMP288 bivalent HSG peptide
Number of subjects: 9
Study 26640780 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 imaging session
Number of subjects: 9
Study 26640780 — intervention group
Group type: EXPERIMENTAL
Intervention: TF2 pharmacokinetics (PK)
Number of subjects: 9
Study 26640780 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In- and (177)Lu-IMP288 pharmacokinetics (PK)
Number of subjects: 9
Study 26640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN/RBV plus NTZ
Number of subjects: 21
Study 26640956 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFN/RBV (historical cohort)
Number of subjects: 21
Study 26641137 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (100 to 400 mg once daily in phase 1, 100 mg twice daily in phase 2)
Number of subjects: 61
Study 26643677 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cord blood transfusion within 5 days postpartum (n = 5)
Number of subjects: 14
Study 26643677 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic red blood cell transfusion when necessary (n = 9; control group)
Number of subjects: 14
Study 26643737 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful drug-eluting stent implantation
Number of subjects: 8454
Study 26643737 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-periprocedural MI
Number of subjects: 8454
Study 26643807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (LY317615) and bevacizumab
Number of subjects: 81
Study 26644412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 183
Study 26644412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant (HCT) after GO
Number of subjects: 183
Study 26644956 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 3384
Study 26644956 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 3384
Study 26644956 — intervention group
Group type: COMPARATOR
Intervention: Desvenlafaxine
Number of subjects: 3384
Study 26644956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3384
Study 26644957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended release (ER)
Number of subjects: 0
Study 26644957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26645295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxia-telangiectasia patients
Number of subjects: 25
Study 26645295 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 26645405 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered intravenously for 60 min after blood-brain barrier disruption using an implantable ultrasound device.
Number of subjects: 1
Study 26645414 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1, -2, -3, -8, -9, -10 and IL-6, IL-8 levels in COPD patients
Number of subjects: 32
Study 26645414 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3, -7, -8, -9, -10 and -12 concentrations
Number of subjects: 32
Study 26645414 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3, -7, -10
Number of subjects: 32
Study 26645414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary MMP concentrations
Number of subjects: 32
Study 26645477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-engagement with trial sites (contacting directors and obtaining letters of intent)
Number of subjects: 33
Study 26645559 — intervention group
Group type: EXPERIMENTAL
Intervention: SeptiCyte Lab (four-gene classifier combining CEACAM4, LAMP1, PLA2G7, and PLAC8 RNA biomarkers)
Number of subjects: 450
Study 26645559 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 450
Study 26645682 — intervention group
Group type: EXPERIMENTAL
Intervention: GA/GG genotype of AKT2: rs33933140
Number of subjects: 261
Study 26645682 — intervention group
Group type: EXPERIMENTAL
Intervention: GT/GG genotype of PI3CA: rs9838117
Number of subjects: 261
Study 26645682 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/TT genotype of AKT2: rs11880261
Number of subjects: 261
Study 26645894 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment in early life
Number of subjects: 450
Study 26645894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 450
Study 26646040 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated Psychosis Syndrome (APS)
Number of subjects: 89
Study 26646040 — intervention group
Group type: COMPARATOR
Intervention: Non-APS youth
Number of subjects: 89
Study 26646680 — intervention group
Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 57
Study 26646680 — intervention group
Group type: COMPARATOR
Intervention: nevirapine-based ART
Number of subjects: 57
Study 26646680 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-naive
Number of subjects: 57
Study 26646811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 1092
Study 26646811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education level
Number of subjects: 1092
Study 26646818 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline optimism
Number of subjects: 164
Study 26646818 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gratitude
Number of subjects: 164
Study 26646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose IL-2
Number of subjects: 36
Study 26646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial learning phase with six different doses and frequencies of IL-2
Number of subjects: 36
Study 26647079 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 0
Study 26647082 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Mammary Artery (IMA) failure
Number of subjects: 1539
Study 26647082 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of IMA graft failure
Number of subjects: 1539
Study 26647082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent clinical outcomes related to IMA failure
Number of subjects: 1539
Study 26647281 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-based vaccine loaded with autologous HIV-1-infected apoptotic cells
Number of subjects: 10
Study 26647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline for 24 weeks with a background regimen of anti-TB drugs
Number of subjects: 233
Study 26647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline treatment
Number of subjects: 233
Study 26647450 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmographic pulse amplitude ratio during Valsalva maneuver
Number of subjects: 102
Study 26647450 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmographic pulse amplitude ratio
Number of subjects: 102
Study 26647454 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (action and maintenance)
Number of subjects: 55
Study 26647454 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (pre-contemplation and contemplation)
Number of subjects: 55
Study 26647901 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT program
Number of subjects: 91
Study 26648747 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy (placebo-controlled)
Number of subjects: 0
Study 26648747 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 0
Study 26648747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26649075 — intervention group
Group type: EXPERIMENTAL
Intervention: MBP-NC (200 mg red yeast rice extract, 500 mg berberine, 10 mg policosanols)
Number of subjects: 60
Study 26649075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26649337 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound (CEUS) with 2.4 ml SonoVue
Number of subjects: 1153